Search

Your search keyword '"Chichareon, Ply"' showing total 365 results
Start Over Author "Chichareon, Ply"
365 results on '"Chichareon, Ply"'

4. Reassessing heart failure therapy in Thailand: Patient insights and treatment outcomes from the Thai heart failure registry

Author

Krittayaphong, Rungroj, Yingchoncharoen, Teerapat, Puwanant, Sarinya, Boonyapiphat, Thanita, Charoenyos, Noppawan, Wongtheptien, Wattana, Chotenimitkhun, Runyawan, Chichareon, Ply, Phrommintikul, Arintaya, Thundee, Chalongchai, Chirakarnjanakorn, Srisakul, Ariyachaipanich, Aekarach, Senthong, Vichai, Kanjanavanich, Rungsrit, Buakhamsri, Adisai, Chantrarat, Thoranis, Ratanasumawong, Kasem, Songmuang, Smonporn Boonyaratavej, Sethalao, Porntera, and Kunjara-Na-Ayudhya, Rapeephon

Published
2024
Full Text
View/download PDF

11. Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial

Author

Gao, Chao, Buszman, Piotr, Buszman, Paweł, Chichareon, Ply, Modolo, Rodrigo, Garg, Scot, Takahashi, Kuniaki, Kawashima, Hideyuki, Wang, Rutao, Chang, Chun Chin, Kogame, Norihiro, Tomaniak, Mariusz, Ono, Masafumi, Hara, Hironori, Slagboom, Ton, Aminian, Adel, Naber, Christoph Kurt, Carrie, Didier, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Geuns, Robert-Jan van, Serruys, Patrick W., and Zurakowski, Aleksander

Published
2021
Full Text
View/download PDF

12. The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial

Author

Wang, Rutao, Takahashi, Kuniaki, Chichareon, Ply, Gao, Chao, Kogame, Norihiro, Modolo, Rodrigo, Tomaniak, Mariusz, Kawashima, Hideyuki, Ono, Masafumi, Hara, Hironori, Schächinger, Volker, Tonev, Gincho, Ungi, Imre, Botelho, Roberto, Eeckhout, Eric, Hamm, Christian, Jüni, Peter, Vranckx, Pascal, Windecker, Stephan, Garg, Scot, Van Geuns, Robert Jan, Onuma, Yoshinobu, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

13. Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS

Author

de Faria, Ana Paula, Modolo, Rodrigo, Chichareon, Ply, Chang, Chun-Chin, Kogame, Norihiro, Tomaniak, Mariusz, Takahashi, Kuniaki, Rademaker-Havinga, Tessa, Wykrzykowska, Joanna, de Winter, Rob J., Ferreira, Rui C., Sousa, Amanda, Lemos, Pedro A., Garg, Scot, Hamm, Christian, Juni, Peter, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Onuma, Yoshinobu, Steg, Philippe Gabriel, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

14. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI

Author

Chichareon, Ply, Modolo, Rodrigo, Kawashima, Hideyuki, Takahashi, Kuniaki, Kogame, Norihiro, Chang, Chun-Chin, Tomaniak, Mariusz, Ono, Masafumi, Walsh, Simon, Suryapranata, Harry, Cotton, James, Koning, Rene, Akin, Ibrahim, Kukreja, Neville, Wykrzykowska, Joanna, Piek, Jan J., Garg, Scot, Hamm, Christian, Steg, Philippe Gabriel, Jüni, Peter, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Onuma, Yoshinobu, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

15. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study

Author

Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Takahashi, Kuniaki, Chang, Chun-Chin, Tomaniak, Mariusz, Botelho, Roberto, Eeckhout, Eric, Hofma, Sjoerd, Trendafilova-Lazarova, Diana, Kőszegi, Zsolt, Iñiguez, Andres, Wykrzykowska, Joanna J., Piek, Jan J., Garg, Scot, Hamm, Christian, Steg, Philippe Gabriel, Jüni, Peter, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Onuma, Yoshinobu, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

16. Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)

Author

Chang, Chun Chin, Spitzer, Ernest, Chichareon, Ply, Takahashi, Kuniaki, Modolo, Rodrigo, Kogame, Norihiro, Tomaniak, Mariusz, Komiyama, Hidenori, Yap, Sing-Chien, Hoole, Stephen P., Gori, Tommaso, Zaman, Azfar, Frey, Bernhard, Ferreira, Rui Cruz, Bertrand, Olivier F., Koh, Tian Hai, Sousa, Amanda, Moschovitis, Aris, van Geuns, Robert-Jan, Steg, Philippe Gabriel, Hamm, Christian, Jüni, Peter, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Serruys, Patrick W., Soliman, Osama, and Onuma, Yoshinobu

Published
2019
Full Text
View/download PDF

17. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

Author

Ono, Masafumi, Chichareon, Ply, Tomaniak, Mariusz, Kawashima, Hideyuki, Takahashi, Kuniaki, Kogame, Norihiro, Modolo, Rodrigo, Hara, Hironori, Gao, Chao, Wang, Rutao, Walsh, Simon, Suryapranata, Harry, da Silva, Pedro Canas, Cotton, James, Koning, René, Akin, Ibrahim, Rensing, Benno J. W. M., Garg, Scot, Wykrzykowska, Joanna J., Piek, Jan J., Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Valgimigli, Marco, Windecker, Stephan, Storey, Robert F., Onuma, Yoshinobu, Vranckx, Pascal, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

18. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

Author

Takahashi, Kuniaki, Kogame, Norihiro, Tomaniak, Mariusz, Chichareon, Ply, Chang, Chun-Chin, Modolo, Rodrigo, Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, van Geuns, Robert Jan, Dominici, Marcello, Huber, Kurt, Buszman, Pawel, Bolognese, Leonardo, Tumscitz, Carlo, Żmudka, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Wykrzykowska, Joanna J., de Winter, Robbert J., Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Valgimigli, Marco, Windecker, Stephan, Vranckx, Pascal, Garg, Scot, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

19. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

Author

Tomaniak, Mariusz, Chichareon, Ply, Klimczak-Tomaniak, Dominika, Takahashi, Kuniaki, Kogame, Norihiro, Modolo, Rodrigo, Wang, Rutao, Ono, Masafumi, Hara, Hironori, Gao, Chao, Kawashima, Hideyuki, Rademaker-Havinga, Tessa, Garg, Scot, Curzen, Nick, Haude, Michael, Kochman, Janusz, Gori, Tommaso, Montalescot, Gilles, Angiolillo, Dominick J., Capodanno, Davide, Storey, Robert F., Hamm, Christian, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Onuma, Yoshinobu, Serruys, Patrick W., and Anderson, Richard

Published
2020
Full Text
View/download PDF

20. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction

Author

Chichareon, Ply, Modolo, Rodrigo, Collet, Carlos, Tenekecioglu, Erhan, Vink, Maarten A., Oh, Pyung Chun, Ahn, Jung-Min, Musto, Carmine, Díaz de la Llera, Luis S., Cho, Young-Seok, Violini, Roberto, Park, Seung-Jung, Suryapranata, Harry, Piek, Jan J., de Winter, Robbert J., Wykrzykowska, Joanna J., Spaulding, Christian, Kang, Woong Chol, Slagboom, Ton, Hofma, Sjoerd H., Wijnbergen, Inge F., Di Lorenzo, Emilio, Pijls, Nico H., Räber, Lorenz, Brugaletta, Salvatore, Sabaté, Manel, Stoll, Hans-Peter, Stone, Gregg W., Windecker, Stephan, Onuma, Yoshinobu, and Serruys, Patrick W.

Published
2019
Full Text
View/download PDF

21. Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease

Author

Kogame, Norihiro, Takahashi, Kuniaki, Tomaniak, Mariusz, Chichareon, Ply, Modolo, Rodrigo, Chang, Chun Chin, Komiyama, Hidenori, Katagiri, Yuki, Asano, Taku, Stables, Rod, Fath-Ordoubadi, Farzin, Walsh, Simon, Sabaté, Manel, Davies, Justin E., Piek, Jan.J., van Geuns, Robert-Jan, Reiber, Johan H.C., Banning, Adrian P., Escaned, Javier, Farooq, Vasim, Serruys, Patrick W., and Onuma, Yoshinobu

Published
2019
Full Text
View/download PDF

22. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

Author

Takahashi, Kuniaki, Serruys, Patrick W., Chichareon, Ply, Chang, Chun Chin, Tomaniak, Mariusz, Modolo, Rodrigo, Kogame, Norihiro, Magro, Michael, Chowdhary, Saqib, Eitel, Ingo, Zweiker, Robert, Ong, Paul, Ottesen, Michael Mundt, Tijssen, Jan G.P., Wykrzykowska, Joanna J., de Winter, Robbert J., Garg, Scot, Stoll, Hans-Peter, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx, Pascal, Carrie, Didier, and Windecker, Stephan

Published
2019
Full Text
View/download PDF

24. Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial: Feasibility, Diagnostic Performance of Quantitative Flow Ratio, and Clinical Prognostic Value of Functional SYNTAX Score Derived From Quantitative Flow Ratio in Patients With 3-Vessel Disease

Author

Asano, Taku, Katagiri, Yuki, Chang, Chun Chin, Kogame, Norihiro, Chichareon, Ply, Takahashi, Kuniaki, Modolo, Rodrigo, Tenekecioglu, Erhan, Collet, Carlos, Jonker, Hans, Appleby, Clare, Zaman, Azfar, van Mieghem, Nicolas, Uren, Neal, Zueco, Javier, Piek, Jan J., Reiber, Johan H.C., Farooq, Vasim, Escaned, Javier, Banning, Adrian P., Serruys, Patrick W., and Onuma, Yoshinobu

Published
2019
Full Text
View/download PDF

25. Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD

Author

Collet, Carlos, Miyazaki, Yosuke, Ryan, Nicola, Asano, Taku, Tenekecioglu, Erhan, Sonck, Jeroen, Andreini, Daniele, Sabate, Manel, Brugaletta, Salvatore, Stables, Rodney H., Bartorelli, Antonio, de Winter, Robbert J., Katagiri, Yuki, Chichareon, Ply, De Maria, Giovanni Luigi, Suwannasom, Pannipa, Cavalcante, Rafael, Jonker, Hans, Morel, Marie-angèle, Cosyns, Bernard, Kappetein, Arie P., Taggart, David T., Farooq, Vasim, Escaned, Javier, Banning, Adrian, Onuma, Yoshinobu, and Serruys, Patrick W.

Published
2018
Full Text
View/download PDF

26. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial

Author

Tijssen, Ruben Y. G., Kerkmeijer, Laura S. M., Katagiri, Yuki, Kraak, Robin P., Takahashi, Kuniaki, Kogame, Norihiro, Chichareon, Ply, Modolo, Rodrigo, Asano, Taku, Nassif, Martina, Kalkman, Deborah N., Sotomi, Yohei, Collet, Carlos, Hofma, Sjoerd H., van der Schaaf, Rene J., Arkenbout, E. Karin, Weevers, Auke P. J. D., Beijk, Marcel A. M., Piek, Jan J., Tijssen, Jan G. P., Henriques, Jose P., de Winter, Robbert J., Onuma, Yoshinobu, Serruys, Patrick W., and Wykrzykowska, Joanna J.

Published
2019
Full Text
View/download PDF

31. Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA2DS2-VASc score.

Author

Methavigul, Komsing, Chichareon, Ply, Yindeengam, Ahthit, and Krittayaphong, Rungroj

Subjects
ORAL medication, ATRIAL fibrillation, ASIANS, PROPORTIONAL hazards models
Abstract

Background: This study was conducted to assess the net clinical benefit (NCB) for oral anticoagulant (OAC) in atrial fibrillation (AF) patients according to the CHA2DS2-VASc score. Methods: Patients with AF were prospectively recruited in the COOL AF Thailand registry from 2014 to 2017. The incidence rate of thromboembolic (TE) events and major bleeding (MB) was calculated. Cox proportional hazards model was used to compare the TE and MB rate in patients with and without OACs in CHA2DS2-VASc score of 0–1 and ≥ 2, respectively. The survival analysis was performed based on CHA2DS2-VASc score. The NCB of OACs was defined as the TE rate prevented minus the MB rate increased multiplied by a weighting factor. Results: A total of 3,402 AF patients were recruited. An average age of patients was 67.38 ± 11.27 years. Compared to non-anticoagulated patients, the Kaplan Meier curve showed anticoagulated patients with CHA2DS2-VASc score of 2 or more had the lower thromboembolic events with statistical significance (p = 0.043) and the higher MB events with statistical significance (p = 0.018). In overall AF patients, there were positive NCB in warfarin patients with CHA2DS2-VASc score of 3 or more while there were positive NCB in DOACs patients regardless of CHA2DS2-VASc score. Females with CHA2DS2-VASc score of 3 or more had a positive NCB regardless of OACs type. Good anticoagulation control (TTR ≥65%) improved an NCB in males with CHA2DS2-VASc score of 3 or more. Conclusions: AF patients with CHA2DS2-VASc score of 3 or more regardless warfarin or DOACs had a positive NCB. The NCB of OACs was more positive for DOACs compared to warfarin and for females compared to males. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events

Author

Hara, Hironori, van Klaveren, David, Takahashi, Kuniaki, Kogame, Norihiro, Chichareon, Ply, Modolo, Rodrigo, Tomaniak, Mariusz, Ono, Masafumi, Kawashima, Hideyuki, Wang, Rutao, Gao, Chao, Niethammer, Margit, Fontos, Geza, Angioi, Michael, Ribeiro, Vasco Gama, Barbato, Emanuele, Leandro, Sergio, Hamm, Christian, Valgimigli, Marco, Windecker, Stephan, Jüni, Peter, Steg, Philippe Gabriel, Verbeeck, Johan, Tijssen, Jan G.P., Sharif, Faisal, Onuma, Yoshinobu, and Serruys, Patrick W.

Published
2020
Full Text
View/download PDF

34. Prognostic Value of Ankle-Brachial Index in Prediction of Cardiovascular Events in an Asian Population with Multiple Atherosclerotic Risk Factors.

Author

Suwannasom, Pannipa, Phinyo, Phichayut, Leemasawat, Krit, Chichareon, Ply, Nantsupawat, Teerapat, Osataphan, Nichanan, Thonghong, Tasalak, Suwanugsorn, Saranyou, Wongvipaporn, Chaiyasith, and Phrommintikul, Arintaya

Subjects
ATHEROSCLEROSIS risk factors, ATHEROSCLEROSIS complications, ANKLE brachial index, CONFIDENCE intervals, MAJOR adverse cardiovascular events, AGE distribution, RISK assessment, ATHEROSCLEROSIS, SEX distribution, DESCRIPTIVE statistics, RESEARCH funding, PREDICTION models, SMOKING, LONGITUDINAL method, PROPORTIONAL hazards models, DISEASE risk factors
Abstract

We aimed to evaluate the incremental prognostic value after incorporation of the ankle-brachial index (ABI) into the 10-year pool cohort equation (PCE) risk model in patients with multiple risk factors (MRFs). A total of 4332 MRFs patients were divided into 2 groups as ABI ≤.9 or >.9. The primary outcome was hard cardiovascular events (hCVE: including cardiovascular death, myocardial infarction, or ischemic stroke) over a median follow-up of 36 months. The Cox proportional hazards survival model, C-statistic, and net reclassification indices (NRI) were used. The occurrence of the primary outcome in the ABI ≤.9 group (3.7%) was significantly greater than in the ABI >.9 group (1.3%), P <.001. ABI is an independent predictor of hCVE in addition to the variables in the standard risk model (age, gender, and smoking status). ABI modestly improved the C-index when added to the PCE risk model (PCE.70 vs ABI+PCE.74). The addition of ABI to the PCE risk model did not significantly improve the classification of patients (NRI -.029; 95% CI: −.215 to.130). Despite ABI being one of the independent predictors of hCVE, integration of ABI into the PCE model did not improve the efficacy of risk reclassification in patients with MRFs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Predicting Infection Related Complications After Endovascular Repair of Infective Native Aortic Aneurysms

Author

Jutidamrongphan, Warissara, primary, Kritpracha, Boonprasit, additional, Sörelius, Karl, additional, Chichareon, Ply, additional, Chongsuvivatwong, Virasakdi, additional, Sungsiri, Jitpreedee, additional, Rookkapan, Sorracha, additional, Premprabha, Dhanakom, additional, Juntarapatin, Pong, additional, Tantarattanapong, Wittawat, additional, and Suwannanon, Ruedeekorn, additional

Published
2022
Full Text
View/download PDF

37. External Validation of the ACUITY/HORIZON Bleeding Risk Score among Acute Coronary Syndrome Patients in Thai PCI Registry

Author

Roongsangmanoon, Worawut, additional, Chichareon, Ply, additional, Angkananard, Teeranan, additional, Suwannasom, Pannipa, additional, Chandavimol, Mann, additional, Limpijankit, Thosaphol, additional, Srimahachota, Suphot, additional, Athisakul, Siriporn, additional, Hutayanon, Pisit, additional, Kiatchoosakun, Songsak, additional, Thanakitcharu, Praprut, additional, Charoenpanichsunti, Montri, additional, Chamsaard, Prajongjit, additional, Siriyotha, Sukanya, additional, Thakkinstian, Ammarin, additional, and Sansanayudh, Nakarin, additional

Published
2022
Full Text
View/download PDF

39. Predicting Infection Related Complications After Endovascular Repair of Infective Native Aortic Aneurysms.

Author

Jutidamrongphan, Warissara, Kritpracha, Boonprasit, Sörelius, Karl, Chichareon, Ply, Chongsuvivatwong, Virasakdi, Sungsiri, Jitpreedee, Rookkapan, Sorracha, Premprabha, Dhanakom, Juntarapatin, Pong, Tantarattanapong, Wittawat, and Suwannanon, Ruedeekorn

Abstract

Endovascular aortic repair (EVAR) as surgical treatment for infective native aortic aneurysm (INAA) is associated with superior survival compared with open surgery, but with the risk of infection related complications (IRCs). This study aimed to assess the association between baseline clinical and computed tomography (CT) features and the risk of post-operative IRCs in patients treated with EVAR for INAA. It also sought to develop a model to predict long term IRCs in patients with abdominal INAA treated with EVAR. All initial clinical details and CT examinations of INAAs between 2005 and 2020 at a major referral hospital were reviewed retrospectively. The images were scrutinised according to aneurysm features, as well as peri-aortic and surrounding organ involvement. Data on post-operative IRCs were found in the patient records. Cox regression analysis was used to derive predictors for IRCs and develop a model to predict five year IRCs after EVAR in abdominal INAA. Of 3 780 patients with the diagnosis of aortic aneurysm or aortitis, 98 (3%) patients were treated with EVAR for abdominal INAAs and were thus included. The mean follow up time was 52 months (range 0 ‒ 163). The mean transaxial diameter was 6.5 ± 2.4 cm (range 2.1 ‒14.7). In the enrolled patients, 38 (39%) presented with rupture. The five year IRC rate in abdominal INAAs was 26%. Female sex, renal insufficiency, positive blood culture, aneurysm diameter, and psoas muscle involvement were predictive of five year IRC in abdominal INAA after EVAR. The model had a C-index of 0.76 (95% CI 0.66 – 0.87). Pre-operative clinical and CT features have the potential to predict IRC after endovascular aortic repair in INAA patients. These findings stress the importance of rigorous clinical, laboratory, and radiological follow up in these patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

Author

Gragnano, Felice, primary, Zwahlen, Marcel, additional, Vranckx, Pascal, additional, Heg, Dik, additional, Schmidlin, Kurt, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Gargiulo, Giuseppe, additional, McFadden, Eugene P., additional, Onuma, Yoshinobu, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Leonardi, Sergio, additional, Zurakowski, Aleksander, additional, Arrivi, Alessio, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Calabrò, Paolo, additional, Serruys, Patrick W., additional, Jüni, Peter, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Gonzalez‐Trevilla, Agustin Albarran, additional, Almeida, Manuel, additional, Neto, Pedro Alves Lemos, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, da Silva, Pedro Canas, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chang, Chun Chin, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Ferreira, Rui Cruz, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Karth, Georg Delle, additional, Dijksma, Lynn, additional, Dominici, Marcello, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath‐Ordoubadi, Farzin, additional, Ferrario, Maurizio, additional, Fontos, Geza, additional, Diaz, Jose Francisco, additional, Quintella, Edgard Freitas, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Ribeiro, Vasco Gama, additional, Garg, Scot, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Antolin, Rosa Ana Hernández, additional, Hildick‐Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Miguel, Carlos Macaya, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean‐François, additional, Moschovitis, Aris, additional, Ottesen, Michael Munndt, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz‐Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker‐Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees‐Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Peñaranda, Antonio Serra, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, Weele, Addy Ter, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova‐Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, van Meijeren, Cokky, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, Dahl, Jürgen Vom, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2022
Full Text
View/download PDF

42. UPDATED WILKINS SCORE BETTER PREDICTS PROCEDURAL SUCCESS OF PERCUTANEOUS BALLOON MITRAL VALVULOPLASTY IN RHEUMATIC MITRAL STENOSIS

Author

Chichareon, Ply, primary, Nilmoje, Thanapon, additional, Suwanugsorn, Saranyou, additional, Chamnarnphol, Noppadol, additional, Wisaratapong, Treechada, additional, Cheewatanakornkul, Sirichai, additional, Limumpornpetch, Sunti, additional, Thungthienthong, Metus, additional, Lohawijarn, Watchara, additional, and Jintapakorn, Woravut, additional

Published
2022
Full Text
View/download PDF

43. Supplemental Material - Prognostic Value of Ankle-Brachial Index in Prediction of Cardiovascular Events in an Asian Population with Multiple Atherosclerotic Risk Factors

Author

Suwannasom, Pannipa, Phinyo, Phichayut, Leemasawat, Krit, Chichareon, Ply, Nantsupawat, Teerapat, Osataphan, Nichanan, Thonghong, Tasalak, Suwanugsorn, Saranyou, Wongvipaporn, Chaiyasith, and Phrommintikul, Arintaya

Subjects
Cardiology
Abstract

Supplemental Material for Prognostic Value of Ankle-Brachial Index in Prediction of Cardiovascular Events in an Asian Population with Multiple Atherosclerotic Risk Factors by Pannipa Suwannasom, MD, PhD, Phichayut Phinyo, MD, PhD, Krit Leemasawat, MD, Ply Chichareon, MD, PhD, Teerapat Nantsupawat, MD, Nichanan Osataphan, MD, Tasalak Thonghong, MD, Saranyou Suwanugsorn, MD, Chaiyasith Wongvipaporn, MD, Arintaya Phrommintikul, MD, and the CORE-Thailand investigators in Angiology

Published
2022
Full Text
View/download PDF

44. External Validation of the ACUITY/HORIZON Bleeding Risk Score among Acute Coronary Syndrome Patients in Thai PCI Registry.

Author

Roongsangmanoon, Worawut, Chichareon, Ply, Angkananard, Teeranan, Suwannasom, Pannipa, Chandavimol, Mann, Limpijankit, Thosaphol, Srimahachota, Suphot, Athisakul, Siriporn, Hutayanon, Pisit, Kiatchoosakun, Songsak, Thanakitcharu, Praprut, Charoenpanichsunti, Montri, Chamsaard, Prajongjit, Siriyotha, Sukanya, Thakkinstian, Ammarin, and Sansanayudh, Nakarin

Published
2023
Full Text
View/download PDF

45. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial

Author

Tomaniak, Mariusz, Chichareon, Ply, Onuma, Yoshinobu, Deliargyris, Efthymios N., Takahashi, Kuniaki, Kogame, Norihiro, Modolo, Rodrigo, Chang, Chun Ching, Rademaker-Havinga, Tessa, Storey, Robert F., Dangas, George D., Bhatt, Deepak L., Angiolillo, Dominick J., Hamm, Christian, Valgimigli, Marco, Windecker, Stephan, Steg, Philippe Gabriel, Vranckx, Pascal, Serruys, Patrick W., Bertrand, Olivier F., Plante, Sylvain, Van Geuns, Robert-Jan, Hofma, Sjoerd H., Royaards, Kees-Jan, Slagboom, Ton, Suryapranata, Harry, Umans, Victor A. W. M., Rensing, Benno, van der Harst, Pim, Magro, Michael, Barbato, Emanuel, Aminian, Adel, Benit, Edouard, Janssens, Luc, Vrolix, Mathias, Buysschaert, Ian, Carrie, Didier, Barraud, Pascal, Teiger, Emmanuel, Koning, Ren, Farzin, Beygui, Morelle, Jean-francois, Isaaz, Karl, Maillard, Luc, Abdellaoui, Mohamed, Brunel, Philippe, Angioi, Michael, Lantelme, Pierre, Sabate, Manel, Albarran Gonzalez-Trevilla, Agustin, Cardiology, Graduate School, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, ACS - Heart failure & arrhythmias, and Cardiovascular Centre (CVC)

Subjects
Male, Ticagrelor, Internationality, Time Factors, medicine.medical_treatment, 030204 cardiovascular system & hematology, Severity of Illness Index, Tertiary Care Centers, Coronary artery disease, 0302 clinical medicine, Cause of Death, 030212 general & internal medicine, 610 Medicine & health, Original Investigation, Aspirin, DUAL ANTIPLATELET THERAPY, Continuity of Patient Care, Clopidogrel, Treatment Outcome, CLOPIDOGREL, Platelet aggregation inhibitor, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, INTERVENTION, medicine.drug, Acute coronary syndrome, medicine.medical_specialty, Hemorrhage, Risk Assessment, Drug Administration Schedule, 03 medical and health sciences, Percutaneous Coronary Intervention, Internal medicine, medicine, Humans, Acute Coronary Syndrome, Dose-Response Relationship, Drug, RECEPTOR, business.industry, Percutaneous coronary intervention, IN-VITRO, medicine.disease, Survival Analysis, PLATO, Conventional PCI, business, Platelet Aggregation Inhibitors, Follow-Up Studies
Abstract

Key PointsQuestionWhat are the benefits and risks of continuing aspirin in addition to P2Y12 receptor inhibition with ticagrelor among patients with acute coronary syndrome between 1 month and 12 months after percutaneous coronary intervention? FindingsIn this nonprespecified, post hoc analysis of the GLOBAL LEADERS randomized clinical trial, beyond 1 month after percutaneous coronary intervention in acute coronary syndrome, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. MeaningThe findings of this hypothesis-generating analysis pave the way for further trials evaluating aspirin-free antiplatelet strategies after percutaneous coronary intervention.ImportanceThe role of aspirin as part of antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. ObjectiveTo evaluate the benefit and risks of aspirin in addition to ticagrelor among patients with ACS beyond 1 month after percutaneous coronary intervention (PCI). Design, Setting, and ParticipantsThis is a nonprespecified, post hoc analysis of GLOBAL LEADERS, a randomized, open-label superiority trial comparing 2 antiplatelet treatment strategies after PCI. The trial included 130 secondary/tertiary care hospitals in different countries, with 15991 unselected patients with stable coronary artery disease or ACS undergoing PCI. Patients had outpatient visits at 1, 3, 6, 12, 18, and 24 months after index procedure. InterventionsThe experimental group received aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy; the reference group received aspirin plus either clopidogrel (stable coronary artery disease) or ticagrelor (ACS) for 12 months, followed by 12-month aspirin monotherapy. In this analysis, we examined the clinical outcomes occurring between 31 days and 365 days after randomization, specifically in patients with ACS who, within this time frame, were assigned to receive either ticagrelor alone or ticagrelor and aspirin. Main Outcomes and MeasuresThe primary outcome was the composite of all-cause death or new Q-wave myocardial infarction. ResultsOf 15968 participants, there were 7487 patients with ACS enrolled; 3750 patients were assigned to the experimental group and 3737 patients to the reference group. Between 31 and 365 days after randomization, the primary outcome occurred in 55 patients (1.5%) in the experimental group and in 75 patients (2.0%) in the reference group (hazard ratio [HR], 0.73; 95% CI, 0.51-1.03; P=.07); investigator-reported Bleeding Academic Research Consortium-defined bleeding type 3 or 5 occurred in 28 patients (0.8%) in the experimental group and in 54 patients (1.5%) in the reference arm (HR, 0.52; 95% CI, 0.33-0.81; P=.004). Conclusions and RelevanceBetween 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. These findings should be interpreted as exploratory and hypothesis generating; however, they pave the way for further trials evaluating aspirin-free antiplatelet strategies after PCI. Trial RegistrationClinicalTrials.gov identifier: NCT01813435.This secondary analysis of the GLOBAL LEADERS randomized clinical trial evaluates the benefit and risks of aspirin in addition to ticagrelor among patients with acute coronary syndrome beyond 1 month after percutaneous coronary intervention.

Published
2019

47. The Influence of Implantation Techniques on Lesion-Oriented Outcomes in Absorb BVS and Xience EES Lesions Treated in Routine Clinical Practice at Complete Three-Year Follow-Up - AIDA Trial QCA Substudy

Author

Tijssen, Ruben Y., primary, Kerkmeijer, Laura S., additional, Takahashi, Kuniaki, additional, Kogame, Norihiro, additional, Katagiri, Yuki, additional, Kraak, Robin P., additional, Chichareon, Ply, additional, Modolo, Rodrigo, additional, Asano, Taku, additional, Nassif, Martina, additional, Kalkman, Deborah N., additional, Sotomi, Yohei, additional, Collet, Carlos, additional, Hofma, Sjoerd H., additional, van der Schaaf, Rene J., additional, Arkenbout, E. Karin, additional, Weevers, Auke, additional, Piek, Jan J., additional, Tijssen, Jan G., additional, Henriques, Jose P., additional, de Winter, Robbert J., additional, Onuma, Yoshinobu, additional, Serruys, Patrick W., additional, and Wykrzykowska, Joanna J., additional

Published
2021
Full Text
View/download PDF

48. Statistical methods for composite endpoints

Author

Hara, Hironori, primary, van Klaveren, David, additional, Kogame, Norihiro, additional, Chichareon, Ply, additional, Modolo, Rodrigo, additional, Tomaniak, Mariusz, additional, Ono, Masafumi, additional, Kawashima, Hideyuki, additional, Takahashi, Kuniaki, additional, Capodanno, Davide, additional, Onuma, Yoshinobu, additional, and Serruys, Patrick W., additional

Published
2021
Full Text
View/download PDF

49. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial: A Post Hoc Analysis of the Global Leaders Trial

Author

Takahashi, Kuniaki, Chichareon, Ply, Modolo, Rodrigo, Kogame, Norihiro, Chang, Chun Chin, Tomaniak, Mariusz, Moschovitis, Aris, Curzen, Nick, Haude, Michael, Jung, Werner, Holmvang, Lene, Garg, Scot, Tijssen, Jan G P, Wykrzykowska, Joanna J, de Winter, Robbert J, Hamm, Christian, Steg, Philippe Gabriel, Stoll, Hans-Peter, Onuma, Yoshinobu, Valgimigli, Marco, Vranckx, Pascal, Windecker, Stephan, Serruys, Patrick W, Graduate School, ACS - Atherosclerosis & ischemic syndromes, Cardiology, ACS - Heart failure & arrhythmias, and ACS - Microcirculation

Subjects
Stable angina, ACS/NSTE-ACS, Adjunctive pharmacotherapy, Drug-eluting stent
Abstract

AIMS: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients with increasing total stent length (TSL). METHODS AND RESULTS: This is a post hoc analysis of the GLOBAL LEADERS trial, a prospective, multicentre, open-label, randomised trial, investigating the impact of the experimental strategy (one-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) versus the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in patients with a Biolimus A9-eluting stent (BES). The primary endpoint was the composite of all-cause death and new Q-wave myocardial infarction (MI), and the secondary endpoint was Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at two years. To investigate the association between total stent length and outcomes, groups were compared in quartiles according to TSL; the fourth quartile group was at significantly higher ischaemic risk at two years. In that stratum (TSL ≥46 mm), the experimental strategy significantly reduced the risk of the primary endpoint (hazard ratio [HR] 0.67, 95% confidence interval [CI]: 0.49-0.90; pinteraction=0.043), while demonstrating a similar risk of BARC type 3 or 5 bleeding (HR 0.99, 95% CI: 0.66-1.49; pinteraction=0.975). CONCLUSIONS: Ticagrelor monotherapy could potentially balance ischaemic and bleeding risks, thereby achieving a net clinical benefit in patients with a TSL ≥46 mm with a BES.

Published
2020

50. Ticagrelor Monotherapy Beyond One Month after PCI in ACS or Stable CAD in Elderly Patients Aged Above 75 Years: a Prespecified Analysis of the Randomized GLOBAL LEADERS Trial

Author

Tomaniak, Mariusz, Chichareon, Ply, Modolo, Rodrigo, Takahashi, Kuniaki, Chang, Chun Chin, Kogame, Norihiro, Spitzer, Ernest, Buszman, Pawel E, Van Geuns, Robert-Jan M, Valkov, Veselin, Steinwender, Clemens, Geisler, Tobias, Prokopczuk, Janusz, Sabaté, Manel, Zmudka, Krzysztof, Rademaker-Havinga, Tessa, Tijssen, Jan G P, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Onuma, Yoshinobu, Vranckx, Pascal, Valgimigli, Marco, Windecker, Stephan, Baber, Usman, Anderson, Richard, Dominici, Marcello, and Serruys, Patrick W

Subjects
610 Medicine & health
Abstract

AIMS Antiplatelet treatment in the elderly post percutaneous coronary interventions (PCI) remains a complex issue. METHODS AND RESULTS A pre-specified analysis of randomized GLOBAL LEADERS (n=15991), comparing 23-month ticagrelor monotherapy (after one month of DAPT) with the reference treatment (12-month DAPT followed by 12 months of aspirin). Among elderly patients (>75 years; n=2565), the primary endpoint (two-year all-cause mortality or new Q-wave corelab-adjudicated myocardial infarction [MI]) occurred in 7.2% and 9.4% of patients in the ticagrelor monotherapy and the reference group, respectively, (hazard ratio [HR]0.75, 95% confidence interval [CI] 0.58-0.99,p=0.041;pint=0.23); BARC-defined bleeding type 3/5 occurred in 5.2% and 4.1%, respectively (HR1.29; 95%CI0.89-1.86;p=0.180;pint=0.06). The elderly with stable CAD had a higher rate of BARC 3/5 type bleeding (HR2.05, 95%CI1.18-3.55) with ticagrelor monotherapy versus the reference treatment (pint=0.02). Elderly patients had a lower rate of definite or probable stent thrombosis (ST) with ticagrelor monotherapy (0.4%vs.1.4%,p=0.015,pint=0.01),compared with the reference group. CONCLUSIONS In this prespecified, exploratory analysis of the overall neutral trial, there was no differential treatment effect of ticagrelor monotherapy (after one-month dual therapy with aspirin) found in elderly patients undergoing PCI with respect to the rate of the primary endpoint of all-cause death or new Q-wave MI. The lower rate of ST in the elderly with ticagrelor monotherapy is hypothesis-generating.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results